Skip to content

Low Level Lazer Therapy Effect on Vertebral Artery Blood Flow in Elderly With Cervical Disc Degeneration

Low Level Lazer Therapy Effect on Vertebral Artery Blood Flow in Elderly With Cervical Disc Degeneration

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06025175
Enrollment
60
Registered
2023-09-06
Start date
2023-09-15
Completion date
2024-01-01
Last updated
2023-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disc Degeneration

Brief summary

This study will include 60 elderly patients with cervical disc degeneration, from both gender who are aged from 60 - 75 years old.

Detailed description

The 60 patients will divided into two groups, with 30 patients in each group. group(A): will receive low level lazer and exercises for three times per week for 12 weeks. Group (B): will receive only exercises. Resistivity index of both right and left vertebral arteries will be measured before and after the 12 weeks.

Interventions

30 patients will receive low level lazer therapy 3 times a week for 12 weeks.

30 patients will receive only routine exercises 3 times a week for 12 weeks.

Sponsors

South Valley University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Two groups Group (A) and group(B)

Eligibility

Sex/Gender
ALL
Age
60 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

1. elderly patients with age range between 60 and 75 years old. 2. with cervical disc degeneration.

Exclusion criteria

1. patients with uncontrolled hypertension. 2. Patients with uncontrolled diabetes mellitus. 3. Patients with severe cardiac or chest diseases.

Design outcomes

Primary

MeasureTime frameDescription
Resistivity index of both right and left vertebral arteries12 weeksResistivity index of both right and left vertebral arteries will be measured before and after the 12 weeks.

Countries

Egypt

Contacts

Primary ContactShymaa Y Abo zaid
shaymaayoussef397@gmail.com01010941685

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026